MedTrace Logo

Observation of Medical Treatments in MBC HER2-negative Patients

NCT02365831 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2016-06-15

No results posted yet for this study

Summary

While therapeutic strategies for HER2-positive breast cancer are well defined, there is not a standard strategy for HER2-negative tumors.

Because of lack of information related to the the factors affecting the choice of a particular treatment strategy, as well as the optimization of the correct sequence of treatments, the choice of the treatment for the advanced disease remains highly empirical and may differ significantly among the different cancer centers.

The purpose of this study is the observation of a cohort of patients with metastatic HER2-negative in terms of:

1. the choice of chemotherapy treatments starting from the first line of treatment;
2. factors that may influence these choices;
3. correlation among the characteristics of patients (age, menopausal status, etc.) and type of adjuvant and metastatic treatment ;
4. clinical outcome (pattern of relapse, time from diagnosis, etc.);
5. evaluation of the adherence to the literature's recommendations for therapeutic sequences in clinical practice.

Conditions

Interventions

OTHER

Observation of treatment management

Group/cohort

Sponsors & Collaborators

  • Clinical Research Technology S.r.l.

    collaborator INDUSTRY

  • Consorzio Oncotech

    lead OTHER

Principal Investigators

  • Marina Cazzaniga, MD · Azienda Ospedaliera San Gerardo-Oncologia Medica (Saint Gerard Hospital-Medical Oncology)

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02365831 on ClinicalTrials.gov